Synthetic Human Secretin in Children With Autism

Completed · Phase 3

Conditions studied: Autism

In brief

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Key facts

Study ID

NCT00036244

Run by

Repligen Corporation

Starts

2002-04-01

Expected to finish

2004-01-01

Last updated by the study team

2005-08-05

Who can join

Age: 3 and older, up to 5. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Southwest Autism Research Center — Phoenix, Arizona, United States
• UCLA Pediatric Neurology — Los Angeles, California, United States
• Children's Hospital and Research Center at Oakland — Oakland, California, United States
• 1st Allergy & Clinical Research Center — Centennial, Colorado, United States
• Alachua Family Psychiatry — Gainesville, Florida, United States
• Miami Children's Hospital — Miami, Florida, United States
• Riley Children's Hospital — Indianapolis, Indiana, United States
• The Clinical Trials Center:A Division of Children's Hospital — Metairie, Louisiana, United States
• Hardy Healthcare Associates — Hingham, Massachusetts, United States
• Children's Hospital of Michigan — Detroit, Michigan, United States
• University of Medicine and Dentistry of New Jersey — Newark, New Jersey, United States
• Schneider Children's Hospital — New Hyde Park, New York, United States
• The Ohio State University — Columbus, Ohio, United States
• Children's Biomedical Center of Utah — Sandy City, Utah, United States
• Puget Sound Neurology — Edmonds, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.